Intramucosal 5-aminosalicyclic acid (5-ASA) and acetylated 5-ASA (Ac-5-ASA) concentrations were determined in ileocolonic biopsy specimens from 61 
between the area under the curve of the serum concentrations and the intramucosal concentrations, supporting the importance of the local availability of the drug. This inverse relationship was absent for the azo-bound drugs. Colonic washout induced mechanical removal of intraluminal 5-ASA with a secondary disturbance in absorption resulting in a rapid decline in the serum concentrations. However, only for Dipentum did this result in significantly lower 5-ASA mucosal concentrations. This is the first reported attempt to evaluate the mucosal availability of 5-ASA after different oral preparations. It shows that where transit time is accelerated higher mucosal concentrations occur after slow release preparations (except for Claversal 250 mg) than after azo-bound drugs. Additional studies are necessary to correlate these concentrations with clinical effects. (Gut 1992; 33: 1338-1342) 5 -Aminosalicylic acid (5-ASA) is the active moiety of sulphasalazine in inflammatory bowel disease. 1-3 Because orally ingested, uncoated 5-ASA is almost completely absorbed in the stomach and the proximal small intestine,4 several methods have been used to delay and prevent this proximal absorption. In delayed release preparations (Asacol, Claversal), 5-ASA is coated with an acrylic based resin that dissolves at a pH greater than 6. In a slow release preparation (Pentasa), 5-ASA is encapsulated in microspheres of ethyl-cellulose that gradually dissolve in the small intestine. Finally, in azobound drugs, bacterial azoreductases liberate two 5-ASA molecules (Dipentum) or split off 5-ASA from sulphapyridine (Salazopyrin) .
The presumptive topical mode of action of 5-ASA56 suggests that it would be best to obtain a maximal concentration at the site of disease (the terminal ileum and colorectum). The urinary output of 5-ASA reflects the fraction that is absorbed in the small intestine, and that is not therefore available for the topical effect; the faecal concentrations represent the residual 5-ASA present in the bowel lumen. An 'ideal' 5-ASA containing preparation would give a low plasma concentration and urinary recovery but high faecal concentration. Faecal concentrations, however, provide only an indirect estimate of the drug available in the tissues. We have therefore developed a high performance liquid chromatography (HPLC) system to determine 5-ASA and its metabolite acetylated 5-ASA (Ac-5-ASA) in biopsy specimen homogenates. We confirmed the presence of 5-ASA in the mucosa by autofluorescence and correlated these concentrations with serum concentration-time curves in healthy volunteers. At the same time we determined Ac-5-ASA concentrations to evaluate the mucosal acetylation.
Finally Ac-5-ASA in serum and in biopsy specimen homogenates as previously described.7 The detection limit for both 5-ASA and Ac-5-ASA in biopsy homogenates was approximately 1 ng; the results were expressed as ng/mg wet wt. The detection limit for serum was 2 ng/ml. (171) relationship is found between the AUC (Table  III) and the mucosal concentrations (Table I ). This inverse relationship is absent for the azobound drugs. Colonic washout reduces rapidly and significantly the serum concentrations of 5-ASA and Ac-5-ASA as seen in Table IV the intestinal transit on urinary and faecal excretion of several 5-ASA preparations was analysed. The diarrhoea induced by the colonic washout in our study provokes mechanical removal of the intraluminal 5-ASA. This results, even in steady state, in a rapid decline in serum concentrations. This reduction excludes early dissolution of the coat by Endopeg (pH 7-4). Although this washout interferes with the pharmacokinetic profiles of the preparations, it is essential for the endoscopy and prevents the contamination of the biopsy specimens with the (Ac-)5-ASA from the stools. Furthermore, we can assume that this mechanical effect is similar for all preparations tested and does not greatly influence the conclusions about the results of the mucosal concentrations.
More difficult to study and quantify is the effect of the washout on the cleavage of the azobond. The acceleration of transit shortens the time available for the bacteria to split the azobond. The sterilisation of the gut by the washout can even prevent the cleavage. This effect seems more important for Dipentum than for Salazopyrin resulting in significantly higher mucosal concentrations in the rectum and sigmoid in patients who had not had previous washout. In contrast, mucosal concentrations after Salazopyrin remain low in both situations.
To minimise the effects of the washout we observed a delay of three hours between the intake of the last dose and the start of the washout to permit drug transit to the ileum, particularly because transit had already been accelerated in the previous three days by laxatives. This delay was based on our serum curves after single doses and on the studies of scintigraphic images of tablet disintegration showing a correlation with serum blood levels of 5-ASA.9 Our serum curves show the start of the release after one to three hours. Apparently no correlation is seen between the time of maximal release (Tmax) and the mucosal concentrations suggesting that although the release pattern of the different drugs has certainly influenced our results, this influence should not be overestimated.
A concentration gradient through the colon is not observed except for a slight predominance in the ileum and right hemicolon after Asacol and Claversal 500 mg corresponding to a large release of the drug.
To our knowledge, no previous studies of mucosal concentrations are available. Faecal concentrations are used as indirect estimates of the local concentrations. Comparative studies of faecal concentrations after different aminosalicylates are few and provide contradictory results. Staerk Laursen et al'°estimated colonic concentrations by means of in vivo dialysis of faeces and found that in patients in steady state with inactive ulcerative colitis concentrations after olsalazine (Dipentum) and Asacol were almost double those seen with equimolar doses of Pentasa and salofalk (Claversal). In contrast, Rijk et al8 evaluated the faecal excretions of healthy volunteers with accelerated transit time after a single dose. The trend in their results was similar to our findings: faecal excretion of 5-ASA was highest after Asacol, followed by Pentasa and Claversal, and lowest after Dipentum and Salazopyrin.
In our study, autofluorescence microscopy confirmed that 5-ASA penetrates the mucosa and does not only cover its surface. Moreover, this covering is reduced to a minimum by the colonic washout. The important differences in intramucosal concentrations after Claversal 250 and 550 mg tablets were intriguing. Both drugs differ not only in terms of the dosage but also in the composition of the coating, giving rise to a different bioavailability.
Finally, we found significant Ac-5-ASA concentrations in the biopsy homogenates. In contrast with serum, the ratios of 5-ASA to Ac-5-ASA are higher than 1, reflecting the abundant supply of 5-ASA. This acetylation is an irreversible" and partially local'2 process. However, the role of this probably therapeutically inactive metabolite"3 remains unclear.
In conclusion, it can be said that during accelerated intestinal transit, slow release preparations, except for Claversal 250 mg tablets, provide higher steady state mucosal concentrations than azo-bound drugs. These concentrations are inversely related to the AUC in serum supporting the role of the local availability of the drugs. Because 
